Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0HEJWD
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ABBV-011
|
|||||
| Synonyms |
ABBV 011; ABBV-011; ABBV-011, SC-011; ABBV011; SC-011
Click to Show/Hide
|
|||||
| Organization |
AbbVie, Inc.
|
|||||
| Drug Status |
Phase 1 (Terminated)
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
SC17
|
Antibody Info | ||||
| Antigen Name |
Seizure protein 6 homolog (SEZ6)
|
Antigen Info | ||||
| Payload Name |
Valeric-acid-calicheamicin
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mc-PEG8-acid-labile linker
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Special Approval(s) |
Orphan drug(EMA)
|
|||||
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Discovered Using Patient-derived Xenograft Model
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT03639194 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 study of ABBV-011 as a single-agent and in combination with budigalimab (ABBV-181) in subjects with relapsed or refractory small cell lung cancer. | ||||
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 15.30% (Day 28) | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 LD(NAC-LD19.10)=0.24 mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU64) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 35.60% (Day 28) | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
|
||||
| In Vivo Model | Small cell lung cancer PDX model (PDX: LU149) | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 42.85% (Day 14) | Negative SEZ6 expression (SEZ6-) | ||
| Method Description |
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
|
||||
| In Vivo Model | Small cell lung cancer PDX model (PDX: LU505) | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 45.90% (Day 21) | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 ADC=8mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU505) | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 71.70% (Day 21) | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 ADC=1 mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU149) | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 87.00% (Day 21) | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
NAC-LD19.10 ADC=8mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU505) | ||||
| Experiment 7 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 89.80% (Day 29) | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 ADC=1 mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU95) | ||||
| Experiment 8 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 89.80% (Day 28) | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
|
||||
| In Vivo Model | Small cell lung cancer PDX model (PDX: LU149) | ||||
| Experiment 9 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 92.00% (Day 28) | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 ADC=0.5 mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU64) | ||||
| Experiment 10 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 93.50% (Day 21) | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 ADC=2 mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU149) | ||||
| Experiment 11 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 94.78% (Day 28) | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
|
||||
| In Vivo Model | Small cell lung cancer PDX model (PDX: LU95) | ||||
| Experiment 12 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 96.00% (Day 28) | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
|
||||
| In Vivo Model | Small cell lung cancer PDX model (PDX: LU64) | ||||
| Experiment 13 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 96.80% (Day 29) | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 ADC=2 mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU95) | ||||
| Experiment 14 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97.00% (Day 29) | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 ADC=4 mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU95) | ||||
| Experiment 15 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98.00% (Day 28) | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 ADC=1 mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU64) | ||||
| Experiment 16 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98.40% (Day 28) | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 ADC=2 mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU64) | ||||
| Experiment 17 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98.70% (Day 21) | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 ADC=4 mg/kg.
|
||||
| In Vivo Model | SCLC PDX model (PDX: LU149) | ||||
| Experiment 18 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.60% (Day 28) | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
|
||||
| In Vivo Model | Small cell lung cancer PDX model (PDX: LU95) | ||||
| Experiment 19 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.80% (Day 28) | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
|
||||
| In Vivo Model | Small cell lung cancer PDX model (PDX: LU95) | ||||
| Experiment 20 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 28) | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
|
||||
| In Vivo Model | Small cell lung cancer PDX model (PDX: LU64) | ||||
| Experiment 21 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 28) | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
|
||||
| In Vivo Model | Small cell lung cancer PDX model (PDX: LU64) | ||||
| Experiment 22 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 28) | Positive SEZ6 expression (SEZ6+++/++) | ||
| Method Description |
ABBV-011 induces efficient tumor cell killing in cell line-derived models of LU64 and LU149 cells with SC17 expression with high expression.
|
||||
| In Vivo Model | Small cell lung cancer PDX model (PDX: LU149) | ||||
References